Expression of tumour progression-associated genes in circulating tumour cells of patients at different stages of prostate cancer

Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer

(2017) Nicholas J. Vogelzang et al.   EUROPEAN UROLOGY

AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide

(2017) Anna Katharina Seitz et al.   EUROPEAN UROLOGY

Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide

(2017) Emmanuel S. Antonarakis et al.   JOURNAL OF CLINICAL ONCOLOGY

AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate

(2017) Tilman Todenhöfer et al.   JOURNAL OF UROLOGY

The stem cell factor (SCF)/c-KIT signalling in testis and prostate cancer

(2017) Henrique J. Cardoso et al.   Journal of Cell Communication and Signaling

Liquid biopsy: ready to guide therapy in advanced prostate cancer?

(2016) Miriam Hegemann et al.   BJU INTERNATIONAL

Clinical Validity of Detecting Circulating Tumor Cells by AdnaTest Assay Compared With Direct Detection of Tumor mRNA in Stabilized Whole Blood, as a Biomarker Predicting Overall Survival for Metastatic Castration-Resistant Prostate Cancer Patients

(2016) Daniel C. Danila et al.   CANCER JOURNAL

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1

(2016) Matthew Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer

(2016) Christian P. Meyer et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Microfluidic enrichment of circulating tumor cells in patients with clinically localized prostate cancer

(2016) Tilman Todenhöfer et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents

(2015) M Crespo et al.   BRITISH JOURNAL OF CANCER

Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer

(2015) Kun Chang et al.   Oncotarget

Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancer

(2015) Christoph Burdelski et al.   Oncotarget

Human Stromal Cells in the Peripheral Zone of the Prostate Promote Tumorigenesis of Prostatic Cancer Stem Cells through Up-regulation of C-Kit Expression

(2015) Yubing Peng et al.   Journal of Cancer

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

(2014) Emmanuel S. Antonarakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers

(2011) A. J. Armstrong et al.   MOLECULAR CANCER RESEARCH

Drug resistance in metastatic castration-resistant prostate cancer

(2010) Bostjan Seruga et al.   Nature Reviews Clinical Oncology

Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells

(2007) Ajay P. Singh et al.   CANCER LETTERS